Synopsis

Source of validity: Scientific
Rating (out of 5): 1

Specialized pro-resolving mediators (SPMs) are a class of bioactive lipid molecules derived from omega-3 fatty acids that play a crucial role in actively resolving inflammation. The rationale for considering SPMs in Parkinson’s Disease (PD) is based on the growing understanding that chronic neuroinflammation contributes to the progression of PD and other neurodegenerative diseases. In preclinical studies, SPMs such as resolvins, protectins, and maresins have demonstrated the ability to reduce neuroinflammation, promote neuronal survival, and modulate microglial activation in animal models of neurodegeneration. For example, research published in Frontiers in Pharmacology (2022) and Journal of Neuroinflammation (2020) suggests that SPMs may help attenuate inflammatory responses and protect dopaminergic neurons in experimental models of PD. However, despite these promising findings in cell and animal studies, there is currently a lack of robust clinical evidence in humans to support the use of SPMs for the treatment or support of Parkinson’s Disease. No large-scale, randomized controlled trials have been published to confirm their efficacy or safety in PD patients. Therefore, while the scientific rationale is sound and early evidence is encouraging, the evidence base remains preliminary (rated 1/5), and SPMs should not be considered a validated or standard therapy for Parkinson’s Disease at this time. Further human trials are needed to determine their true therapeutic potential in this context.

More about specialized pro-resolving mediators (SPMs)
More about Parkinson's Disease

Other ingredients used for Parkinson's Disease

Other health conditions supported by specialized pro-resolving mediators (SPMs)

Products containing specialized pro-resolving mediators (SPMs)